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OBJECTIVES 
 
  Generate CXCR4 and CCR5, as Cyan (CFP) and Yellow (YFP) fluorescent fusion 
proteins by DNA transfection of plasmids containing inserts of the corresponding 
cDNAs. 
 
 Determine the expression patterns of CXCR4 CFP, CXCR4 YFP, CCR5 CFP and 
CCR5YFP. 
 
 Analyze the functionality of the fusion proteins created.  
 
 Study and determine putative homo- and hetero dimers of CXCR4 and CCR5 by 
Fluorescence Resonance Energy Transfer (FRET).  
 
 Study the dynamics of the different mono-, and oligomeric forms of CXCR4 and 
CCR5, and determine if this affects HIV infection of cells.   
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SUMMARY 
 
The chemokines and their receptors constitute many important physiological functions in the 
human body. The chemokine receptors belong to the family of G-protein coupled receptors, 
characterized by 7 α-helices penetrating the cell membrane, and are coupled to a 
heterotrimeric G-protein intracellularily. Discovering the phenomenon of oligomerization of 
the G-protein coupled receptors, increased the complexity in terms of functionality and 
dynamics significantly, amplifying both challenges and possibilities related to these receptors. 
The chemokine receptors CCR5 and CXCR4 are physiologically diverse and in addition, the 
two co-receptors for HIV-1. HIV-1 infects T cells through an envelope protein called gp120, 
which binds to CD4 on the target cell, in addition to CCR5, CXCR4 or both, depending on the 
strain of the virus in question. M-tropic HIV-1 gp120 enters and infects monocytes via CCR5, 
while the T-tropic HIV-1 p120 enters and infects lymphocytes via CXCR4. Another dual 
tropic strain, entering via both chemokine receptors also exists. Evidence has been published, 
which indicates a possible effect on HIV-1 infection related to receptor oligomerization 
dynamics, based on the presence of several receptors capable of forming oligomeric 
complexes at the cell membrane. In this project, cell functionality and receptor expression 
pattern of CCR5 and CXCR4 fused with a fluorescent protein (CFP or YFP) is demonstrated. 
In addition to this, homo- and heterodimerization between CCR5 and CXCR4 in live cells are 
demonstrated by the use of Fluorescence Resonance Energy Transfer (FRET). By the same 
technique, it is also demonstrated that CCR5 is able to decrease the apparent affinity of 
CXCR4 towards forming homodimers, indicating the conformation dynamics of these 
receptors. Finally, the importance of CXCR4 conformations in terms of T-tropic (X4) HIV-1 
entry is assessed, as it is demonstrated that the presence of CCR5 at the cell surface decreases 
T-tropic (X4) HIV-1 infection significantly, most likely by interacting with CXCR4 and 
altering its conformation.  
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INTRODUCTION 
 
 
 
 
 
 
 
 
 
You gain strength, courage and confidence by every experience in which you really stop to look fear in the face. 
You must do the thing you think you cannot do.  
- Eleanor Roosevelt (1884-1962) 
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In this project, the two chemokine receptors CCR5 and CXCR4 have been studied in greater 
detail. The chemokine receptors, belonging to the G-protein coupled receptors, are important 
due to their presence in the human body and their diverse physiological function. The 
attention devoted to these receptors increased even more after the discovery of the 
phenomenon of oligomerization among the different G-protein coupled receptors. This 
phenomenon amplifies greatly the pharmacological diversity of these receptors, and 
determining the functions of the different complexes may contribute to discover new 
therapeutic possibilities against a wide range of pathologies. 
 
1.1 Chemokines 
 
Chemokines belong to a family of low molecular weight proteins (6-14 kDa), which control a 
wide variety of biological and pathological processes.  In contrast to cytokines that share 
many of the same biological functions, chemokines signal through G-protein coupled 
receptors (GPCRs) at the cell membrane, modulating among other things immune 
surveillance, inflammation processes, chemotaxis, cell migration, cancer and viral infections.  
Although sequence identity of the various chemokines varies from less than 20% to over 90%, 
they all form similar three-dimensional monomer folds, which contain a flexible N-terminal 
domain followed by an N- terminal loop, a three-stranded antiparallell β-sheet region and 
finally a C- terminal α-helix [1].  
Chemokines are traditionally divided into 4 families, based on relative positioning of the first 
two of four highly conserved cysteine residues.  Accordingly, there are; CXC, CC, C and 
CX3C chemokines. The first two comprise the main families. In the CXC family members (α-
chemokines), the first two cysteine residues are separated by a single non-conserved amino 
acid, while the first two cysteine residues are adjacent in the chemokines of the CC family (β-
chemokines) [2].  The less common C family (Ω-chemokines) lacks the first and the third of 
the cysteine residues, while the CX3C family (γ-chemokines), with only one member 
discovered at present, has three amino acids between the first two conserved cysteine 
residues. Nonetheless, for many years the chemokines were classified on the basis of their 
biological functions or the cells producing the chemokines. This resulted in a chaotic system, 
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and a new nomenclature regime was therefore introduced in 2000, in which every chemokine 
was classified into a subfamily based on the coding gene for the specific protein in the 
chromosome [3]. Today, nevertheless, chemokines continue to be generally classified on 
functional criteria, and hence, scientists commonly distinguish between homeostatic and 
inflammatory chemokines.  
A)       B) 
 
 
 
 
Figure 1.1 A) Three dimensional structure of the monomeric (left) and the dimeric form (right) of the 
CC chemokine family. B) Three dimensional structure of the monomeric (left) and the dimeric form 
(right) of the CXC chemokine family [4]. 
 
Homeostatic chemokines are constitutively expressed in the body. They play an important 
role in maintaining the homeostasis of the immune system by coordinating cellular 
movement, such as B- and T-cell migration towards specific secondary lymphoid organs. 
Homeostatic chemokines are also present in other parts of the body, like skin, intestinal 
mucosa and lung tissue, where they contribute to migration and/or activation of different 
kinds of leukocytes. Examples of homeostatic chemokines are CCL19, CCL21 and CXCL12.  
Inflammatory chemokines are in contrast to homeostatic chemokines inductively expressed by 
a variety of cells, not only within the immune system, but also by other cell types as a 
response to specific stimuli. The pro-inflammatory mediators (IFN-γ, pathogens, TNF, etc.) 
act as such stimuli, provoking the expression of these chemokines following for example an 
infection. The chemokines then contribute importantly to direct the cellular response towards 
the damaged, infected and/or inflamed area. Examples of inflammatory chemokines are 
CCL5, CCL3 and CXCL10. 
Through mutagenesis-based studies, it has been possible to identify the binding domains and 
the region of the chemokines implicated in the signalling through their respective receptors 
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[5]. It has been demonstrated that the N-terminus plays a very important role in signalling, 
and that some chemokines, for instance CCL2, CCL5 and CCL9, can bind to their respective 
receptor, but are not capable of signalling if this region is mutated [5, 6]. For some 
chemokines, the activity depends on the first amino acid residue at the N-terminus. For 
example, erasing the 7 first amino acid residues at the extreme end of the N-terminus of CCL2 
gives rise to an antagonist [6, 7]. If the serine residue at the extreme end of the N-terminus of 
CCL2 or CCL5 is followed by a methionine residue, chemokine antagonists are formed 
through peptide signalling retention. The addition of an oxi pentamino group to the extreme 
end of the N-terminus of CCL5 gives rise to a protein blocking HIV viral entry[8]. The 
affinity of CXCL12 to the receptor CXCR4 depends on the RFFESH residues (12-17 amino 
acid residues) [9]. Thus, the functions of the chemokines depend to a great extent on the N-
terminal amino acid sequences.  
 
1.2 Chemokine Receptors 
 
The chemokines exert their functions through binding to their respective receptors, which 
belong to the heptahelical, seven transmembrane domain G-protein coupled receptor family 
(GPCRs). This protein superfamily is one of the most common in the proteome of mammals 
[10], and it is estimated that half of all modern drugs available today act through these 
receptors [11]. Based on sequence homology, GPCRs are classified into 5 main families; 
1. Rhodopsine (701 members). 
a. α-group includes 5 subgroups; prostaglandins, receptors of neurotransmitters, 
melatonin receptors and MECAs. 
b. β-group includes 36 members. No subgroup classification. 
c. γ-group includes 3 subgroups. Chemokine receptors, SOG and MCH (Melanin 
Concentrating Hormone).  
d. δ-group includes 4 subgroups. Receptors related to the oncogene MAS, 
glycoprotein-related receptors, purine receptors and olfactory receptors. [12] 
2. Glutamate (15 members). 
3. Adhesion (24 members) 
4. Frizzled (24 members) 
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5. Secretine (15 members) [12] 
The chemokine receptors are mainly classified into a CC and CXC family, containing 11 and 
7 members, respectively. The classification is based upon the four groups of ligands which 
they bind to (CC, CXC, CX3C and XC). In addition to these chemokine receptors, are also the 
non-functional (silenced) receptors D6 and DUFFY, CCX CKR receptors, and a few virally 
expressed receptors. The chemokine receptors consist of a single polypeptide of 350 amino 
acids, with a molecular mass of about 40 kDa. They are characterized by seven α-helices and 
penetrate the plasma membrane seven times, exposing the N-terminal and 3 loops to the 
extracellular site of the cell, allowing for interaction with ligands. The C-terminus and 3 loops 
are located on the intracellular side of the plasma membrane and are responsible for 
transmitting the signals via G-proteins to the interior of the cell. A motif called DRYLAIV is 
found exclusively in the second intracellular loop of chemokine receptors. This motif is 
implicated in the activation of the intracellular signalling. The binding of the ligand provokes 
a conformational change in this motif, such that the tyrosine139 residue originally oriented 
towards the interior of the receptor, turns to the exterior of the receptor, towards the 
cytoplasm (Fig. 1.2). This is a compulsory conformational change for signalling and the first 
of several, initiating the signal transmission. In fact, the mutant CCR2bY139F, lacking 
tyrosine139, is incapable of transmitting signals, and is therefore non-functional [13]. The so-
called “silenced” receptors (D6 and DUFFY) miss the DRYLAIV motif and this is one of the 
reasons for their non-functionality.  Currently, no tertiary structural model of the chemokine 
receptor exists. The only present tertiary structural models of GPCRs are the rhodopsine 
receptor [14], the β2 adrenergic receptor[15] and the bacterial rhodopsine receptor,  in 
unicellular organisms [16].  
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Figure 1.2: Structure of the chemokine receptor in the cell membrane. The DRYLAIV motif, the 
binding site of the ligand, the binding site of the G-protein as well as that of the kinesis family GRK 
(Section 1.2.1) are all represented in the figure. Courtesy of José Miguel Rodriguez-Frade, CNB, 
Madrid.  
 
 
 
 
 
 
 
 
 
 
22 
 
 
Table 1.1: Overview of the chemokine receptors and their corresponding ligands. Data taken 
from [17]. 
 
 
 
RECEPTORS CORRESPONDING LIGANDS 
CCR1 CCL3, CCL5, CCL7, CCL13, CCL14, CCL15, CCL16, CCL23 
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 
CCR3 CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL16, CCL24, CCL26, CCL28 
CCR4 CCL17, CCL22 
CCR5 CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, CCL16 
CCR6 CCL20 
CCR7 CCL19, CCL21 
CCR8 CCL1 
CCR9 CCL25 
CCR10 CCL27, CCL28 
CXCR1 CXCL6, CXCL7, CXCL8 
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5 CXCL6, CXCL7, CXCL8 
CXCR3A CXCL9, CXCL10, CXCL11 
CXCR3B CXCL4, CXCL9, CXCL10, CXCL11 
CXCR4 CXCL12 
CXCR5 CXCXL13 
CXCR6 CXCL16 
CXCR7 CXCL12 
XCR1 XCL1, XCL2 
CX3CR1 CX3CL1 
CCX-CKR CCL19, CCL21, CCL25 
D6 CCL2, CCL3, CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL22 
DARC/Duffy CCL2, CCL7, CCL8, CCL11, CCL13, CCL14, CCL16, CCL17, CXCL1, CXCL5, CXCL6, 
CXCL8, CXCL9, CXCL11, CXCL13 
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1.2.1  Receptor Activation 
 
Most chemokine receptors activate intracellular heterotrimeric Gi proteins, and their 
signalling cascade is therefore blocked by Pertussis Toxin (PTx) treatment. Other G proteins 
have also been described to be implicated in signalling, such as G13 and Gq, depending on the 
cell type evaluated. The stable and inactive complex of the G-protein contains a GDP 
molecule in the α-subunit. As the G-protein is activated upon signalling through the 
chemokine receptor, this GDP molecule is exchanged by GTP, which in turn activates the α-
subunit and results in the dissociation of the βγ-subunit. The α-subunit connects to the 
receptor, while the βγ- complex remains anchored to the cell membrane. Depending on the 
signal to be delivered, one of the subunits transmits this. As the α-subunit possesses 
enzymatic GTPase activity, the GTP molecule is rapidly hydrolyzed into GDP, and the G-
protein is thereby turned back to its inactive state. The Gα-GDP complex has a high affinity 
for the βγ complex, and the three subunits are joined together again, ready for the next 
activation cycle (Fig. 1.3). Several proteins are implicated in the regulation of these processes. 
Among these are the Regulators of G-protein Signalling (RGS) which associate with the Gα-
GTP complex and act as GTPase activating proteins (GAPs), accelerating the hydrolysis of 
the GTP molecules and thereby regulating the active state of the G-protein and the duration of 
the signalling. Serine-threonine kinases named GRKs are also capable of regulating the 
activation of the G-proteins. These proteins only phosphorylate the receptor in its active form, 
at the serine and threonine residues. At the same time they act as binding sites for arrestins, 
blocking the access of another G-protein to the receptor and thereby inhibit further signalling.  
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Figure 1.3: The G-protein activation cycle. Various types of G-protein α-subunits exist, and the four 
main groups are Gαs, Gαi, Gαq and Gα12. Signalling routes depend on the type of α-subunit, but it is 
still not clear if the attachment of a specific G-protein to the chemokine receptor depends on of the 
cellular environment or simply that the other G-proteins are somehow inhibited. Courtesy of José 
Miguel Rodriguez-Frade, CNB, Madrid.  
 
The G-proteins activate a broad spectre of signalling cascades, ranging from the activation of 
Phospholipase C (PLC), the phosphate kinesis 3’phosphoinositol (PI3K) to the Mitogen 
Activated Protein Kinesis (MAPK cascade) (Fig. 1.4).  
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Figure 1.4 Signalling pathways activated by chemokines and chemokine receptors. Courtesy of José 
Miguel Rodriguez-Frade, CNB, Madrid.  
 
Although activation of PLC is basically induced by G-proteins insensitive to PTx (ex. Gq), 
PLC activation produced by PTx sensitive chemokines through the βγ-complex has been 
described [18]. Activation of PLC promotes the hydrolysis of phosphoinsoitol bisphosphate 
(PIP2), forming inositol triphosphate (IP3) and Diaglycerol (DAG). IP3 interacts with several 
receptors in the Endoplasmatic Reticulum (ER), which results in Ca
2+
 release from its lumen. 
In addition, IP3 is metabolized by a protein kinase phosphorylating IP3 at position 3, forming 
inositoltetraphosphate (IP4), which acts as a second messenger implicated in controlling Ca
2+
 
release through specific channels in the cell membrane. Ca
2+
 and DAG activate different 
cytoplasmic, as well as nuclear signalling cascades. It is also a well known fact that 
chemokines from the CC-family induce activation of Phospholipase A (PLA2), and liberation 
of arachidonic acid in monocytes.  
Phosphatinositol-3 kinase is an enzyme formed by a regulatory and a catalytic subunit which 
facilitate the entry of a phosphate group to position D3 of phosphatidyl inositol lipids. These 
lipids play a role in the signalling pathways implicated in cellular growth and the organization 
of the cytoskeleton. Upon binding of the chemokine to its receptor, the chemokine activates a 
heterodimer of PI3K, capable of phosphorylate PtdIns, PtdIns(4)P and PtdIns(4,5)P2 which in 
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turn act as second messengers to proteins as PKC and AKT, in addition to the signalling 
pathways related to Ras [19].  
The activation of neutrophils by chemoattractants results in activation of the GTPase Ras, 
which in turn activates the MAPK signalling cascade through binding of the Ser/Thr kinase 
Raf. Activation of MAPK through IL-8 binding to the receptors CXCR1 and CXCR2 
transfected into Jurkat cells have also been described [20]. The MAPK signalling cascade has 
many functions, most of them related to gene expression controlling basic cellular 
mechanism, such as mitosis, cell proliferation, differentiation and survival or death.   
 
1.2.2  Attachment of chemokines to the chemokine receptor 
 
Most of the GPCRs belonging to Rhodopsine family contain two highly conserved cysteine 
residues, which form a disulfuric bridge between the first and second extracellular loop. The 
chemokine receptors contain two additional highly conserved cysteine residues, through 
which a second disulfuric bridge is formed, between the N-terminus and the third extracellular 
loop. These two bridges play important roles in the binding and correct positioning of the 
ligand and hence the capacity of the receptor to pass the signal on to the interior of the cell 
(Fig. 1.5).  
The regions implicated in ligand binding have been identified through mutagenesis-based 
studies and by generating chimeric proteins. For some chemokine receptors, ex. CCR5, the N-
terminus is critical for maintaining specificity to the different ligands. The globular domain of 
the chemokine interacts with the receptor through the second extracellular loop, thus 
reorienting the N-terminus so that it points to the transmembrane regions of the receptor [21]. 
The chemokine receptors undergo glycosylation and/or sulfation of tyrosine residues at the N-
terminus [22]. These processes increase the affinity of the receptor to its ligands, and in the 
case of CXCR4 and CCR5, facilitate the entry of the Human Immunodeficiency Virus.  
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Figure 1.5: CCL5 attaching to its receptor CCR5. (a) The initial binding of the chemokine to its 
receptor is based on electrostatic interactions between the negative charge of the second extracellular 
loop of the receptor and the positive charge of the surface of the chemokine. (b) The first contact is 
made between the N-terminus of the ligand and the second extracellular loop of the receptor. (c) The 
ligand-receptor complex formed stabilizes the active form of CCR5 [23]. 
 
1.2.3  Oligomerization of chemokine receptors 
 
The activity of GPCRs was originally related to the monomeric conformation of the receptors, 
but increasing evidence began to indicate that GPCRs can heterodimerize, or even 
oligomerize. The first evidence of these possible active conformations was published by 
Agnati et al. in 1980 [24], but it remained a controversial statement for a long time. Evidence 
showing that active forms of class A GPCRs always exist as either homo, heterodimers or 
oligomeric complexes has been published [25]. However, evidence claiming the monomeric 
form to be the functional unit, hence neglecting the existence of the dimers of this GPCR 
family also exists [26]. In the case of glutamate GPCRs, there is no doubt that the minimal 
functional conformation consists of dimers, and its mechanism for dimerization, as well as its 
signalling mechanism has been well studied. The transmembrane regions of this receptor play 
an important part in interaction with the G-protein. The α-helices of these regions are crucial 
for dimerization, in addition to several other domains of the receptor, as ex. the Venus Flytrap 
domain (VFT) at the N-terminus and the cysteine rich domains (CRD) located between VFT 
and the α-helices of the transmembrane regions. The glutamate GPCR dimers are believed to 
be covalent attached to each other, as several energy interactions, affinity and half life assays 
have shown them to be very stable [27]. Dimerization of the GPCRs can occur at different 
28 
 
regions, depending on the type of GPCR. Dimerization can occur at the N-terminus 
(glutamate receptors and ion channels), the C-terminus(γ-receptors) or at the transmembrane 
regions (the D2 dopamine receptors, and the β adrenergic receptors)[28]. For some receptors, 
dimerization is essential for localization in the cell membrane. This is for example the case of 
the β2adrenergic receptors. Dimerization of these receptors occurs already in the ER [29], and 
they are transported to the cell membrane in this oligomeric form. It has been suggested that 
dimerization and activation of the glutamate receptors are interdependent, although recent 
studies indicate that only one of the two receptors forming the dimer are required for 
interaction with the G-protein. This supports the fact that the ratio of the dimer/G-protein 
complex is 1:1 [27]. This also corresponds with studies showing that regulation through 
interactions with arrestins only requires one of the two receptors of the dimer to bind to this 
protein [30].  
As for the chemokine receptors, an increasing amount of evidence also proves that these 
GPCRs dimerize or oligomerize. Early experiments demonstrated that CXCR4, CCR5 and 
CCR2 form dimers [31-33]. At that point, and probably because of the instability of the 
complexes as a result of the treatment with several detergents, it was also concluded that the 
ligands promoted the formation of dimers. Later studies based on co-immunoprecipitation and 
energy transfer techniques like Bioluminescence Resonance Energy Transfer (BRET) and 
Fluorescence Resonance Energy Transfer (FRET) demonstrated that the homo- and 
heterodimers of  CCR5 and CCR2 are present in the cell membrane in the absence of ligands 
[34, 35], and that the homodimerization of CCR5 occurs during synthesis in the ER [33]. In 
this receptor, the Ile52 and Val150 amino acid residues (in TMI and TMIV respectively) play 
an important role in the dimerization process, and mutation of either one of these amino acid 
residues disables the ability of the receptor to dimerize and thus results in loss of function 
[36]. The ability of several chemokine receptors as well as other GPCR mutants to dimerize 
with the non-mutants, and retain these in different intracellular compartments has also been 
described, as f. ex. the natural mutant CCR5Δ32S and CCR5 [37].  
Differences in functionality between the different receptor conformations have been detected. 
For example, the signalling pathway of CCR2/CCR5 shows some differences compared to 
that of the homodimers alone. [38]. Another example is the heterodimer CXCR4/CXCR7, 
which intensifies the signalling promoted by CXCL12 during embryonic development [39].  
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Allosteric modulation of the chemokine receptor function after binding of an antagonist to one 
of the receptors has also been demonstrated.  For example, binding of an antagonist to the 
trans complex CCR2/CXCR4, inhibits the binding of the ligand of the other [40].  
Heterodimerization between CCR5 and CXCR4 was claimed not to exist in 2002 [33]. Later, 
it was demonstrated that heterodimers of CCR5 and CXCR4 are formed in activated T-cells in 
the immunological synapses, where they act together as an oligomeric complex promoting a 
specific signalling pathway [41]. In 2008, heterodimers of CXCR4 and CCR5 were described 
outside the immunological synapse in FRET studies [42] and subsequently in BRET studies 
in 2009 [43]. It has also been showed that the respective ligands of CCR5 and CXCR4 
modulate the dimer conformations in opposite manners, as the ligand of CXCR4 decrease 
dimer formation while the ligand of CCR5 promotes heterodimerization between CCR5 and 
CXCR4 [42].  
There are still many cases of homo- and heterodimerization between chemokine receptors left 
to discover, as well as between other GPCRs. Recent evidence even indicates that both 
receptor expression and ligand binding modulate the chemokine receptor conformations [44]. 
Oligomerization of the chemokine receptors is thus today a well accepted phenomenon. 
Current debates revolve mainly around the functional relevance of the different 
conformations, if or to which extent they are dynamic and, if so, what controls their dynamics.  
 
1.2.4  CXCR4, CCR5 and their ligands in physiological and pathological 
processes 
 
The chemokine receptors and their ligands are implicated in a vast multitude of physiological, 
as well as pathological processes. Although a specific chemokine can bind to various 
receptors and one specific receptor can interact with various chemokines, each binding results 
in a specific cellular signal, depending on the cell at which the binding takes place, its 
localization in the body and the physiological status of the cell at the moment of the 
signalling. In the following sections, the most important pathological and physiological 
functions of CCR5, CXCR4 and their respective chemokines (CCL5 and CXCL12) will be 
shortly discussed.  
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1.2.4.1  Embryonic development 
 
CXCL12 and its receptor CXCR4 (as well as CXCR7) play a very important role in 
embryonic development. Deletion of CXCR4 or CXCL12 in mice gives rise to a lethal 
phenotype, characterized by several cardiac defects (dysplasia of the septic ventricle), 
hematopoietic defects (deficiency of lymphopoiesis of B-cells and myelopoiesis of the bone 
marrow) and abnormal development of the cerebellum [45]. 
 
1.2.4.2  Immune system 
 
Homeostasis of the immune system depends completely upon mobility of the immunological 
cells. The hematopoietic precursors complete their differentiation in an adult individual 
through a process in which CXCR4/CXCL12 interaction is essential [46]. CXCR4 also 
contributes significantly to the lymphatic recirculation (“homing”) of B-cells to the lymph 
nodes.  
 
1.2.4.3  Tumours 
 
Even though angiogenesis and metastasis are two similar processes involving cell mobility, 
there are mechanisms by which tumours metastase independently of angiogenesis. CXCR4 
and CXCL12 seem to be of major importance in the metastasis of breast cancer tumours to the 
lungs (generally one of the first organs to which metastasis occurs)[47]. Other cancer types 
metastase through other chemokine receptors. 
 
1.2.4.4  Autoimmune diseases 
 
CXCR4, CCR5 and their ligands also play a role in autoimmune illnesses [48] and regulation 
of the neuroendocrine system [47, 49]. It has for example been demonstrated that CXCL12 
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and CCL5 are involved in Rheumatoid Arthritis [50],  multiple sclerosis [49, 51]and in 
Diabetes type I [52].  
 
1.2.5 The Role of CXCR4 and CCR5 in HIV Infection 
 
CXCR4 and CCR5 are perhaps best known as the co-receptors of the Human 
Immunodeficiency Virus type 1 (HIV-1), the causative agent of Acquired Immunodeficiency 
Syndrome (AIDS). HIV infection of white blood cells (lymphocytes and monocytes) occurs 
through binding of a viral envelope glycoprotein called gp120 to CD4 and CXCR4 and/or 
CCR5 (Fig 1.6) [53], depending of the viral strain in question. The X4 (T-tropic) strain infects 
lymphocytes (T cells), while the R5 (M-tropic) strain infects monocytes. Dual-tropic strains 
infecting both cell types exist, using both co-receptors [54] Binding of the envelope 
glycoprotein to CD4 and the chemokine receptor(s), leads to membrane fusion, and the viral 
genome enters the host cell, integrating viral DNA, after reverse transcription of RNA, in the 
host cell DNA. The host cell starts producing viral proteins, including new envelope 
glycoproteins which are transported to the host cell surface where they can assemble with 
other viral proteins to form new virion particles. The break-through discovery regarding the 
role of CCR5 and CXCR4 in HIV infection turned these chemokine receptors into very 
promising HIV therapy targets, and some of the currently available HIV drugs act on these 
receptors. Individuals with natural mutations of the CCR5 receptor exist (CCR5Δ32), having 
a significantly reduced risk of infection or a delay in the development towards AIDS [31]. 
CCR5Δ32 is not transported to the cell membrane and is therefore rapidly degraded. It is, 
however, capable of dimerizing with CCR5, retaining this receptor in different intracellular 
compartments and decreasing its expression in the cell membrane [37]. Some scientists 
proposed a possible negative dominance of the mutant as an explanation for the delay in the 
development of HIV towards AIDS, but this was later rejected, as it was demonstrated that the 
decrease in the expression of CCR5 in the cell membrane was due to a decrease in gene 
dosage [55]. 
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Figure 1.6: The reproductive cycle of HIV. (a) Binding.  The HIV virion binds to the CD4 receptor, 
and subsequently to the co-receptor(s). (b) Fusion. HIV fuses with the cell membrane. Virion core is 
released into the host cell. (c) Reverse transcription. The single stranded viral RNA is converted to 
double stranded viral DNA. (d) Integration. The double stranded viral DNA is integrated into host cell 
DNA. (e) Transcription. Host cell RNA polymerase copies the HIV genomic material and generates 
messenger (m) RNA. Long chains of viral proteins are produced from the mRNA. (f) Regulator 
proteins. Increase HIV gene expression dramatically. (g) Assembly. The long chain of viral proteins is 
hydrolyzed and cut into small functional proteins by the HIV enzyme protease. New virions are formed 
with the small functional proteins and new RNA. (h) Budding. The new virion uses a cellular envelope 
as cover and exit the host cell through budding. Taken from www.drugdiscoverytoday.com 
 
The external envelope glycoprotein (gp120) of HIV binds to the CD4 receptor on the cell, and 
this binding promotes a conformational change in the gp120 envelope, resulting in the 
exposure of a domain known as the CD4 induced (CD4i) domain. This domain, in 
conjunction with the third hypervariable region (V3 loop) of the HIV is crucial for recognition 
and binding to the co-receptors [56]. The details of this mechanism are currently not clear, but 
it is likely to be complex, as both the CD4i domain and the V3 loop are implicated. Studies 
have also demonstrated that the V3 loop is a major determinant of HIV-1 tropism. The V3 
loop is a surface-accessible loop formed by a disulfide bridge between two invariant cysteins 
at positions 296 and 330 of gp120 [57]. Two functionally distinct regions of gp120 for 
binding to CCR5 have recently been discovered, designated as the stem and the crown. Both 
have been shown to be necessary for binding, but the V3 crown alone determines the receptor 
specificity of the virus [58]. It has also been demonstrated that the R5 virus dominates in early 
infection, but that the virus switches to X4 in about 50% as the disease progresses. This 
switch is associated with a worsening of prognosis, and is hence of importance in a direct 
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clinical context. There are several hypotheses explaining this receptor preference switch, but 
no mechanism or reason for the switch has been determined yet [59]. Medicinal treatment of 
HIV-1 infection normally involves a mixture of drugs with different mechanisms of action, as 
for example protease antagonists, reverse transcriptase blockers and fusion inhibitors. Several 
CCR5 and CXCR4 antagonists have shown themselves able to decrease infection in vitro, but 
this may not be related to in vivo conditions. In Norway, Maraviroc® is the only drug existing 
with a chemokine receptor antagonist mechanism. This drug binds to CCR5 at its ligand 
binding site and thereby blocks binding to the viral gp120 envelope. Maraviroc® has no effect 
on T-tropic HIV-1 at all in vivo. The necessity of finding new strategies based on the 
chemokine receptors to block or decrease infection is therefore highly present, and revealing 
the dynamics of the conformations of the receptors implicated in HIV infection may 
contribute importantly to this. 
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1.3  Techniques 
 
1.3.1 Flow Cytometry 
 
Flow Cytometry is a powerful technique used to identify the properties of individual cells 
within heterogeneous populations, suspended in fluid. Cells are labelled with a fluorescent 
antibody, and passed one by one through a laser beam. The light emitted as the cells pass 
through the laser beam is collected by the cytometer and processed by a suitable data system.  
 
 
 
 
Figure 1.7: The different elements of a flow Cytometer. (flow.csc.mrc.ac.uk/?page_id=302) 
 
A cytometer consists of three main parts:  
 
The fluidic system 
The main point of the fluid system is to disperse the cells randomly in fluid, and transport 
them one by one to the interrogation point. The flow cell is a major part of the fluidic system. 
This consists of a narrowing core channel, through which the cell sample is injected under 
pressure. Surrounding this core channel is an outer and bigger channel filled up with sheath 
fluid. Due to the physics of the flow cell, the outer channel always has a lower 
pressure than the core channel, but the fluid flows faster than the injected cell 
sample. This difference in pressure and velocity between the two channels 
creates a huge drag on the injected cell sample, which allocates the cells in a 
row, forcing them to pass one by one through the laser beam. This effect is 
called hydrodynamically focusing [60]. 
Figure 1.8: The flow cell of a cytometer. (flow.csc.mrc.ac.uk/?page_id=302) 
35 
 
 
The laser 
The laser is the light source and it is responsible for the emission of light from the cells. The 
light scattered from the cell is gathered and directed to detectors which collects the light at 
specific wavelengths. 
 
The electronics/ data system 
Light emitted is transformed into quantitative results by suitable data systems. These systems 
may vary depending on the laboratory and the purpose of the experiment. 
 
Several flow Cytometry-based techniques have been used in this project: 
 
1.3.1.1 Calcium Assays 
 
Calcium assays were performed in order to assure the physiological function of the cells in 
spite of a fluorescent protein attached to the receptor. As activation of the chemokine receptor 
release calcium flux from the ER in the cell, the function of the receptor can be determined by 
measuring the calcium flux upon activating the receptor with its respective chemokine. Fluo-3 
AM was used as a Calcium indicator, having its excitation wavelength in the green 
fluorescent spectrum. Fluo-3 acts as a calcium chelator in the cells, enabling visualization of 
the calcium flux upon receptor activation.   
 
1.3.1.2 Staining 
 
Staining has in this project been performed in order to determine the percentage of receptors 
expressed at the cell surface. Low expression could be a consequence of the transfection 
process, old, overgrown or in other ways damaged cells, internalization of the receptor or poor 
36 
 
DNA quality. The cells were incubated with a specific antibody to the receptor of interest, and 
this antibody is then attached to a secondary antibody labelled with a fluorescent colour 
enabling identification of the receptor by flow Cytometry.  
 
1.3.2 Resonance Energy Transfer (RET)  
 
The technique of RET is based on the quantitative theory of energy transfer through 
resonance, developed by Förster (1946-1949). It is used to study the interaction between two 
proteins, with one acting as a donor (D), and the other as an acceptor (A). In an electronic 
exited state, the donor will transfer energy to the receiver through dipole-dipole interactions, 
only if the donor and the acceptor are located close enough. As the acceptor absorbs all the 
energy from the donor there is no loss of energy, hence no emission of photons and the whole 
process is therefore non-radioactive.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9: Mechanism of A) Fluorescence Resonance Energy Transfer (FRET) and B) 
Bioluminescence Resonance Energy Transfer (BRET). C) RET shown in the context of dimers in the 
cell membrane [61]. 
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Two techniques have been developed to take advantage of this principle in in vivo studies; 
Fluorescence Resonance Energy Transfer (FRET) and Bioluminescence Resonance Energy 
Transfer (BRET). These are very similar techniques, only differenced by the type of 
luminescence markers. FRET has been used in this project.  
 
1.3.2.1 Basic Principles of FRET 
 
FRET is based on the techniques explained in Section 2.2.1, with at least one of the two 
proteins studied being fluorescent, although laboratories prefer both of the proteins in FRET 
experiments to be fluorescent. The characteristic fluorometric spectra of the different 
fluorescent proteins allow the energy transfer between these to be modulated and measured.  
A)        B) 
 
 
 
 
 
 
 
Figure 2.4: A) Absorption and B) Emission spectra of the different fluorochromes. (Dep. of Oncology 
& Immunology, CNB, Madrid, Spain).  
  
It is of major importance that the fluorescent donors and acceptors fulfil certain requirements; 
1- The emission spectrum of the donor should overlap the absorbance spectrum of the 
acceptor. 
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2- Donor and Acceptor should be sufficiently aligned for the dipole-dipole energy 
transmission to be possible. The orientation of the proteins is also of importance and a 
major factor to consider when analyzing the energy transfer between the two.  
3- The distance between the two proteins should be approximately 10 nanometres for the 
energy transfer to be possible. Each pair of fluorescent proteins has its specific 
distance. 
Table 1.2: FRET pairs with their respective donor and acceptor excitation and emission wavelengths. 
Courtesy of Laura Martinez-Muñoz, CNB, Madrid. 
 
According to Förster’s theory, the efficiency (Et) of the energy transfer is inversely 
proportional to the sixth potency of the distance that separates the two proteins. This gives 
Et = R0
6
 / R
6
 + R0
6
 
R = the distance separating the two fluorescent proteins 
R0 = the distance separating the donor and the acceptor where 50% of the exited energy is 
transferred from the donor to the acceptor, and the other 50% is either lost to radiation or not. 
The efficiency of the energy transfer is in other words highly dependent on the distance 
between the two fluorescent proteins.    
Positive FRET signals hence indicate protein interaction. It is, however, important to be aware 
of the fact that negative FRET signals are not necessarily suggesting lack of dimerization.  
FRET PAIR Exmax 
DONOR 
(nm) 
Em-max 
ACCEPTOR 
(nm) 
BFP2-mGFP 383 507 
CFP-YFP 440 527 
Cerulean-Venus 440 528 
GFP-mCherry 489 510 
Venus-mCherry 528 610 
Venus-tdTomato 528 581 
Venus-mPlum 528 649 
Cy3-Cy5 554 670 
GFP-Cy3 489 566 
GFP-YFP 489 527 
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There are several methods of measuring the efficiency of FRET, once the donor has been 
excited. I will discuss two of these methods, which have been used in this project. 
 
1.3.2.1.1 Acceptor Sensibilization (Saturation Curves) 
 
This method is perhaps the simplest in order to detect FRET efficiency. FRET can be 
measured using a confocal microscopy, taking only one cell into consideration at a time, or it 
may be measured through a fluorescence lector with specific detectors, taking whole cell 
populations into account (Section 3.7). The fluorochrome of the donor protein is exited at its 
specific wave length and the emission of light is obtained through two detection filters which 
detect wavelengths equivalent to that of the donor and the acceptor. The saturation curves of 
FRET are obtained by maintaining the quantity of CFP (fused to the donor receptor) and 
varying the quantity of YFP (fused to the acceptor receptor). By doing this, different ratios of 
YFP/CFP are obtained, and the efficiency of FRET can be calculated for each ratio. Cells 
expressing only YFP (pEYFP-N1) or CFP (pECFP-N1) serve as an internal control, while 
cells co-expressing both CFP and YFP without any receptor, serve as a positive control. 
FRET is measured by the use of an excitation filter of 400 nm (ranging between 393 nm – 403 
nm) and two emission filters of 510 nm ± 8 and 530 ± 8 nm for CFP and YFP, respectively. 
Emission is collected in both channels, and the same conditions are maintained during the 
whole measurement process, so that the relative contribution constants of the fluorophores in 
the detection channels are kept unchanged. This would be a perfect way to measure FRET, 
but one problem exists; exciting the donor protein will always result in a certain amount of 
excitation and emission from the fluorochrome of the acceptor protein as well, although this 
has a higher excitation wave length. Therefore, some of the FRET shown when exiting the 
donor protein may not be due to FRET, but to an actual excitation of the acceptor protein. 
This effect is called “crosslinking”, and as a consequence, control measurements are needed 
in order to find the true FRET efficiency value. FRET must be measured in cells expressing 
only the donor protein fused to its fluorescent protein and cells expressing only the acceptor 
protein fused to its fluorescent protein. The FRET efficiency obtained in these cells enables 
the determination of the amount of crosslinking between the excitation and the emission 
channel, and it is used to normalize the FRET values of the cells co-expressing the donor and 
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the acceptor fused to CFP and YFP, respectively. Zimmerman et al. have developed several 
mathematical equations in order to calculate the fluorescence emitted individually by the 
donor and the acceptor independently, taking all the above mentioned parameters into 
consideration (Spectral Un-Mixing) [62]. These equations have been used in this project: 
Q = Ch510 nm / Ch530 
R = (YFP530 nm Q – YFP510 ) / (CFP510 nm – CFP530 nm Q) 
Where Ch510 nm and Ch530 represent the detected signals in the channels of 510 nm and 530 
nm, respectively.  
The normalized values of the fluorescent proteins FluoCFP and FluoYFP in the channels of 
510 nm and 530 nm, calculated with the control samples of CFP and YFP alone, are 
represented as YFP530nm510nm and CFP510nm530nm. 
Fluorescence is then calculated for each of the proteins: 
FluoCFP = S/ (1+(1/R)) 
Fluo YFP = S / (1+R) 
Where S = Ch510nm + Ch530nm 
Hence, FRET efficiency is: 
FRETeff = Fluo YFP / S 
The calculated FRET efficiency values are put into a graphic system where the x-axis 
represents the ratio YFP/CFP, and the y-axis represents the FRET efficiency measured. A 
theoretic parameter also used is that of FRET50, reflecting the ratio at which 50% of the 
receptors undergo FRET. This value can be regarded as the apparent affinity of the two 
receptors.  
Due to the mathematical equations for calculating the FRET efficiency, only the FRET values 
of saturation curves with at least one receptor in common can be compared to each other. 
Thus, the FRET values of the homodimers of two receptors cannot be compared, but the 
FRET values of their respective heterodimer can be compared to those of their homodimers. 
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1.3.2.1.2 Acceptor Photobleaching 
 
This method requires the use of a confocal microscope. It is based on the fact that the 
intensity of the fluorescence of the donor is decreased in the presence of FRET, because a 
major part of the exited energy is transferred to the acceptor. When the acceptor protein is 
bleached by the use of specific lasers, the extinction effect of the acceptor towards the donor 
is eliminated, and as a consequence, the fluorescent intensity emitted by the donor increases 
significantly. Care must be taken as the acceptor protein is bleached, so that the donor protein 
is not degraded. Four separate images are taken of the receptors coupled to CFP and YFP in a 
selected cell region, before and after bleaching (CFPpre, CFPpost, YFPpre and YFPpost). 
FRET efficiency can then be considered as; 
E = 1-(Ida/Id) 
Where: 
1- Ida = the intensity of the donor’s fluorescence after bleaching the acceptor 
2- Id = the intensity of the donor’s fluorescence before bleaching the acceptor  
One of the major advantages of this method is that it enables us to study the interaction 
between two proteins of a single cell at the time, focusing on specific parts of the cell, for 
example the cell membrane, as has been done in this project. However, the photobleaching 
method has some disadvantages. Dynamic studies are impossible, as the cells are fixed. In 
addition to this, Photobleaching is a destructive technique, as the acceptor protein is destroyed 
in the process. Furthermore, it allows us to measure the FRET of each cell only once. The 
results obtained are also only based on one cell, and the interaction between the two proteins 
in a specific region of this cell. Several images should therefore be taken during the 
experiment (approximately 50-100 cells), in order to obtain FRET efficiency which is 
representative of the population. However, one should keep in mind that images of 100 cells 
are still a very minor pool of any cell population. When using the photobleaching method, 
certain things should be taken into consideration; 
1- Functionality and maintained levels of the proteins in question should be assured, as 
they are fused to a fluorescent protein. Functional assays should therefore be 
completed before initiating further experiments. 
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2- Because the cells are cotransfected, it is essential that the levels of both the donor and 
acceptor proteins are determined. The intensity of the emission of the fluorescence of 
both should be similar; they should thus exist in a ratio of approximately 1:1.  
 
A specific plugin measures pixel by pixel of the 4 separate images taken (CFPpre, CFPpost, 
YFPpre and YFPpost), with a correct donor/acceptor ratio, bearing in mind the pixel number 
of CFP and YFP before and after bleaching the acceptor protein, and the percentage of 
bleaching of the acceptor protein. The plugin also subtracts the intensity background of CFP 
from every image and analyzed region (pre and post). FRET efficiency is hence calculated 
according to the following formula: 
EFRET = ((ICFPpost – ICFPpre) / ICFPpost) x 100 
Where: 
ICFPpre = The emitted florescence collected of CFP before bleaching 
IYFPpre = The emitted florescence collected of YFP before bleaching 
ICFPpost = The emitted florescence collected of CFP after bleaching. 
As negative controls, the fluorescence intensity (pixels) of CFP is measured in cells only 
transfected with CCR5 CFP before and after bleaching. The percentage of FRET efficiency 
obtained in these controls is subtracted from all the other evaluated images of cells containing 
both donor and acceptor proteins. FRET efficiency is finally calculated by the mean value of 
three independent experiments, each of which containing at least 50 images. Although 
fluorescence oversaturated regions are intentionally avoided as the experiment is carried out, 
the fluorescence of CFP and YFP in oversaturated regions are determined in the images 
before bleaching, using the program ImageJ, so that only regions with a ratio YFP/CFP of 1-
1.5 are included in the analysis.  
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1.3.3 In Vitro Determination of T-tropic HIV-1 Infection by Cell-Cell Fusion Assay 
 
HIV-1 infects cells by interacting with the receptors CD4 and CXCR4 or CCR5. Infection 
capacity can be evaluated by monitoring cell-cell fusions between cells containing the 
envelope glycoprotein gp120 (effector cells) and cells containing the necessary receptors for 
infection (target cells), using Firefly and Renilla Luciferases as reporters. The target cells are 
co-transfected with Firefly and Renilla Luciferases under the control of a T7 promoter. Firefly 
and Renilla Luciferases catalyze reactions resulting in light emission as beetle luciferin and 
coelenterazin, their respective substrates, are added.  
 
 
 
 
 
 
 
Figure 2.5: The catalytic reactions of Firefly Luciferase (above) and Renilla Luciferase (under). 
Taken from www.promega.com 
 
As Firefly and Renilla Luciferases are both intracellular proteins, cell lysis prior to assessing 
light intensity is necessary. The commercial kit (Dual-Glo® Luciferase Assay System 
(Promega) used in these experiments, allows for independent measurements of both Firefly 
and Renilla Luciferase bioluminescence, as the Renilla Luciferase substrate solution contains 
a reagent quenching the Firefly Luciferase reaction, decreasing it approximately 10 000 fold. 
As the T7 promoter is activated by the T7 DNA polymerase upon fusion of the effector cells 
and the target cells, light intensities produced by Firefly Luciferase can be considered as a 
reflection of the infection occurred. The Firefly Luciferase intensity in non-infected cells can 
be considered as background luminescence, as these cells have not fused with the effector 
cells, and hence do not contain the T7 promoter. The light intensity produced by the reaction 
catalyzed by Renilla Luciferase does not depend on the cells being infected or not, it only 
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depends on the amount of DNA transfected. Thus, the light obtained from the Renilla 
Luciferase catalyzed reaction is used for calculating Firefly /Renilla Luciferase ratios from the 
different cell samples, normalizing each sample in order to avoid falsification of the results by 
background luminescence. The relative ratio of each point is finally calculated by dividing the 
normalized experimental ratios of the infected cells, by the normalized negative control ratios 
of the corresponding non-infected cells. The relative ratios of the infected cells can be 
compared, and a decrease in value reflects less infection.  
 
 
 
 
 
 
 
 
 
  Figure 2.6: Cell-cell fusion of effectors and target cells [63]. 
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1.3.4 Internalization Assays 
 
Upon stimulation with their respective ligands, the chemokine receptors internalize into the 
cell, and disappear from the cell membrane. This is a good way of measuring the effect of the 
presence of a certain chemokine receptor, as the whole receptor is removed from the cell 
membrane. Internalization can be visualized by for example Flow Cytometry staining, using 
antibodies against the specific receptor. The minimum intensity of the peak is of importance 
in these assays, as this value represents the mean intensity of the fluorescence of the receptors. 
As the receptor internalizes, the minimum intensity value decreases.  
 
1.3.5 Protein Quantification by Bradford’s Method 
 
Bradford (Bio-Rad Protein Assay) is a protein quantification assay, in which a differential 
colour change of an acidic dye occurs upon reaction with varying amounts of proteins in an 
acidic solution. Measurement is done at 595 nm, and protein concentration can be calculated 
by extrapolating a standard curve, where the x- axis represents the concentration (mg/ml) and 
the y- axis represents the light absorbance.  
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MATERIALS & METHODS 
 
 
 
 
 
 
 
 
 
Science is not belief, but the will to find out.  
-Anonymous 
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2.1 Vectors and Constructions 
 
The human receptors CXCR4 and CCR5, kindly donated by Dr. B. Moser (Cardiff 
University), were amplified by PCR from pcDNA3- CXCR4 or pcDNA3-CCR5 constructs 
using specific oligonucleotides, and cloned into pECFP-N1 and pEYFP-N1 (Clontech). 
Routinely, all generated plasmids were sequenced to assure correct ligation of DNA into the 
vectors. The oligonucleotides (primers) used were:  
CXCR4_CFP/CXCR4_YFP:  
Forward: 5´HindIII(5´CTCAAGCTTCGAATTCTGCAGATGTCCATTCCTTTGCCTTTG 
CCTCTTTTG3´) 
Reverse: 3´AgeI(5´GACCGGTGGATCCCGTAAGCTGGAGTGAAAACTTGAAG3´)  
CCR5_CFP/CCR5_YFP:                    
Forward: 5´HindIII(5´TAA AGC TTA TGG ATT ATC AAG TGT CAA GTC C 3´)  
Reverse: 3´AgeI (5´GAC CGG TAA TAA CAA GCC CAC AGA TAT TTC 3´) 
 
2.2 Cell lines 
 
The cell lines HEK293 and 293T Italy (human kidney embryonic cells) were obtained from 
the American Type Culture Collection. The cells were cultivated in DMEM (Biowhittaker, 
USA) supplemented by 10% (v/v) Foetal Bovine Serum (GIBCO), 2 mM L-Glutamine and 1 
mM sodium pyruvate. Cells were diluted every 48 hours, and cultured at 37°C and 5% CO2. 
 
2.3  Chemokines and Antibodies 
 
The chemokines CCL5 (Rantes) and CXCL12 (SDF-1α) were obtained from Peprotech 
(London, England). The antibodies used were anti human CCR5 (Biolegend, California, 
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USA.), anti human CXCR4 (R&D Systems, Minneapolis, USA) and anti human CD4-PE 
(Beckman Coulter, England.) 
 
2.4  Transient Transfection Assays 
 
All the experiments included transiently transfected cells by JetPEI (Polyplus Transfection), 
except the FRET saturation curves which required transfection by polyethylenimine PEI 
(SIGMA-Aldrich). 293T Italy cells were plated in suitable plates and transfected with the 
vector(s) of interest 24 hours later, according to the manufacturer’s protocol.  Experiments 
were carried out after 48 hours incubation at 37°C and 5% CO2. Transfection of Firefly and 
Renilla Luciferases only required 24 hours of incubation at 37°C and 5% CO2.  
 
Transfection by jet PEI included; 
Mixture 1: 50 μl of 150 mM NaCl per 3 x 1010 cells + the correct amount of DNA of the 
receptor of interest. 
Mixture 2: 50 μl of 150 mM NaCl per 3 x 1010 cells + 2 x the amount of DNA of JetPEI. 
Both mixtures were vortexed during approximately 10 seconds. Mixture 2 was added to 
mixture 1 and the mixture was vortexed for another 10 seconds. The mixture was then left to 
incubate 30 minutes at room temperature, after which it was added droplet by droplet to the 
cell plate. The whole process was done in lamina flow hoods.  
 
Transfection by PEI included; 
Mixture 1: 25 μl of 150 mM NaCl per μg DNA (minimum 200 μl 150 mM NaCl). Vortexed 
for 10 seconds. 
Mixture 2: 150 mM NaCl and PEI (5.47 mM nitrogen residues) in a ratio of 5:1. 
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Mixture 2 was added to mixture 1 in a ratio of 1:1 and vortexed for 10 seconds. The mixture 
was then left to incubate at room temperature for 15-30 minutes, after which non-
supplemented DMEM was added to the mixture, in order to add a volume of 1.5 ml/8x10
5
 
cells to each well of cells. After 4 hours of incubation at 37 °C the cell medium was replaced 
by 2 ml 10% (v/v) supplemented DMEM per 8x10
5
 cells. The experiment was carried out 48 
hours of incubation at 37°C.  
 
2.5  Calcium Flux Assays 
 
293T Italy cells were transfected with the fluorescent receptor of interest using JetPEI 
according to the protocol of the fabricant. 48 hours later, the transfection of the cells was 
assured by microscopy. The cells were then lifted with 0.2% (v/v) Ethylene Diamine Tetra 
Acetic acid (EDTA) and 5x10
5
 cells per sample were resuspended in 250 μl supplemented 
10% (v/v) DMEM per sample. Fluo-3 was added (16 μl/ 106 cells) to the cells. Protected from 
light, the cells were left to incubate at 37°C for 30 minutes under constant movement. After 
incubation, the cells were washed with 10% (v/v) supplemented DMEM and centrifuged at 
1200 rpm for 5 minutes after which they were resuspended in 1 ml 10% (v/v) supplemented 
DMEM per 0.5x10
10 
cells. 2 mM CaCl2/ 0.5x10
10
cells was added and the cells were divided 
into the correct amount of duplicated samples and added to Cytometry tubes. Cells were left 
at 37°C for approximately 5 minutes, before they were analyzed by flow Cytometry (Coulter 
Epics XL-MCL) 
 
2.6  Receptor level determination by Flow Cytometry staining 
 
Cells were transiently transfected by JetPEI with the receptors of interest, according to the 
manufacturer’s protocol. 48 hours later, 2.5x105 cells per well were resuspended in 100 μl 
PBS staining (PBS + 1% (v/v) Foetal Bovine Serum + 0.5% (w/v) Bovine Serum Albumin) 
per well and placed in transparent plates of 96 wells with v-shaped bottoms. Following 
centrifuging at 1200 rpm for 5 minutes, the primary antibody was added at its correct 
concentration and left to incubate for 30 minutes. Cells were then washed with PBS staining 
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and centrifuged at 1200 rpm for 5 minutes, before the secondary antibody containing a 
specific fluorochrome was added at its correct concentration and left to incubate for 30 
minutes. Cells were then washed with PBS staining, centrifuged at 1200 rpm for 5 minutes 
and resuspended in 100 μl of PBS. The cells were added to approximately 200 μl isotone in 
special Cytometry tubes, and passed through the flow cytometer (Coulter Epics XL-MCL) 
 
2.7  Saturation Curves 
 
Plating 
4x10
5
 cells per well were plated in plates of 6 wells (p6w) in a volume of 2 ml 10% (v/v) 
supplemented DMEM per well, in the necessary wells to duplicate the predetermined amount 
of YFP/CFP ratio points, and the necessary controls (Section 1.3.2.1.1). Cells were then left to 
incubate at 37°C and 5% CO2 for 24 hours. 
Transfection 
24 hours after plating, the cells were transfected with the relevant receptors fused to 
fluorescent proteins, in order to obtain both YFP/CFP ratios of the receptors, and the different 
control samples (Section 1.3.2.1.1) by PEI, each well separately, in duplicate.  Cells were then 
left to incubate in 10% (v/v) supplemented DMEM at 37°C and 5% CO2 for 48 hours, after 
which the transfection of the cells was assured in the microscope, checking that YFP amounts 
increased in correlation to the amount transfected in every point, and that CFP was maintained 
in all points. 
Measurement 
The cells in each well were then lifted and washed with 1 ml of Hanks Balanced Salt Solution 
(HBSS) supplemented with 0.1% (w/v) glucose at 37 °C. Cells were centrifuged at 1200 rpm 
for 5 minutes. The cells in each well were then resuspended in 240 μl of the same 
supplemented HBSS. As each well needed to contain the same amount of protein, the protein 
amount was quantified by Bradford’s method (2.9), and the protein amount was adjusted to 
0.2 μg/μl per point. 100 μl of each point were finally added to black plates of 96 wells, every 
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point distributed in duplicates, and fluorescence was analyzed by the fluorimetre Wallac 
Envision 2104 Multilabel Reader (Section 1.3.2.1.1).  
 
2.8  Acceptor Photobleaching 
 
Plating 
10x10 mm crystals were deposited in plates of 24 wells (p24w), draped with poly-L-lysine 
(20 μg/ml, diluted in PBS) and left to incubate for 1 hour at 37°C. 5x104 cells per well were 
then plated over the crystals in a volume of 500 μl of 10% (v/v) supplemented DMEM and 
left to incubate for 24 hours at 37°C and 5% CO2.  
Transfection 
The cells were transfected with the corresponding receptors fused to fluorescent proteins by 
JetPEI, according to the manufacturer’s protocol, and left to incubate in 10% (v/v) 
supplemented DMEM at 37°C and 5% CO2 for 48 hours. After incubation, the transfection of 
the cells was assured by microscopy.  
Measurement 
The cells in each well were treated with 4% (v/v) Formaldehyde during 2-3 minutes, in order 
for the cell conformations on the crystals to freeze (fixate). Afterwards, the cells were washed 
several times with PBS. Using a drop of glue solution (80% (v/v) glycerol and 20% (v/v) PBS 
at pH 7), the crystals were glued onto a microscope slide, preventing bubble formation. The 
edges were fixed with blank nail polish and left to dry, before analyses by confocal 
microscopy. The microscope slides were stored in the dark, due to the fluorescence, and at 
4°C due to the instability of the glue solution. The samples were analyzed by the confocal 
microscope Olympus Flowview 1X81. Different lasers were used in order to excite the donor 
(D) and the acceptor (A) protein. The donor protein (D), in this case CCR5 CFP, was excited 
using a diode laser of 405 nm wavelength (12% potency: 25 mW), while the acceptor protein 
(A), being CXCR4 YFP, was excited using an argon laser of 515 nm wavelength (10% 
potency: 45 mW). A dual dicroic mirror of 405-440 / 515 nm was used in both cases. The 
emitted florescence passed through a dicroic mirror of SDM 510 nm and was collected by a 
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detector in the range between 460-500 nm for CFP (ICFPpre). The fluorescence emitted by 
YFP was collected by filtrating light in a range between 530-570 nm (IYFPpre). The YFP 
protein was bleached by increasing the argon laser of 515 nm to maximum potency during 
approximately 5-10 seconds. Once 60-90% elimination of the YFP protein was achieved, 
fluorescence intensities of CFP and YFP were measured again, using the same parameters as 
before (ICFP post, IYFP post). FRET efficiency was finally determined using the program 
IMAGE J 1.37r (Wayne Rasband) (Section 1.3.2.1.2).  
 
2.9  Protein Quantification by Bradford’s method 
 
200 μl of 20% (v/v) Bradford solution diluted in HBSS was added to the necessary wells of a 
plain-bottomed transparent plate of 96 wells. 20 μl of each cell sample was added to a well 
containing the Bradford solution, in addition to a standard curve. Light absorbance was 
measured in the fluorimetre Tecan Infinite M200.  
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2.10  Cell-Cell Fusion Assay 
 
Cells from the cell line HEK 293 were chosen as target cells for this assay, because they 
express CXCR4 endogenously. HEK 293T cells were used as a negative control, as they do 
not contain the CD4 receptor, and stable HEK 293 CD4 cells were used as a positive control, 
as they contain both co-receptors necessary for T-tropic gp120 binding. Two cell lines 
containing different amounts of CCR5 were used to measure T-tropic viral infection in the 
pilot cell-cell fusion assay. HEK 293 CD4 cells transiently transfected with increasing 
amounts of CCR5 were used in further cell-cell fusion assays. 
 
Plating 
Target cells  
1.5x10
5
 cells per well of each cell type (negative control, positive control and cells containing 
CCR5) were plated in duplicate, in a volume of 1 ml 10% (v/v) supplemented DMEM in 
plates of 24 wells (p24w), and left to incubate at 37°C and 5% CO2 for 24 hours. 
Effector cells 
24 hours after plating the target cells, 2x10
6
 HEK 293T cells were plated in a volume of 10 ml 
10% (v/v) supplemented DMEM plate of 100 mm diameters (p100).  
 
Transfection  
Target cells in the pilot assay: 
24 hours after plating the target cells, cells were transfected with Renilla Luciferase and 
Firefly Luciferase under the control of the T7 promoter by JetPEI, according to the 
manufacturer’s protocol. Cells were incubated in 10% supplemented DMEM during 48 hours. 
Target cells in further cell-cell fusion assays: 
24 hours after plating the target cells, these were transfected with increasing amounts of 
CCR5 (0.5 μg – 2 μg). The positive control cells (HEK 293 CD4 cells) were transfected with 
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the empty vector pcDNA3). All cells were transfected by Renilla Luciferase and Firefly 
Luciferase under the control of the T7 promoter. Transfection was done by JetPEI, according 
to the manufacturer’s protocol. Cells were incubated in 10% supplemented DMEM during 48 
hours. 
Effector cells 
24 hours after plating the effector cells, the envelope protein containing T-tropic gp120 (IIIB) 
and T7 polymerase were introduced into these cells by infection with recombinant vaccinia 
virus (vv-env-1) containing gp120, 8 μl virus/ 5x105 cells. Cells were then incubated in 2% 
supplemented DMEM and 100 μg/ml rifampicine during 24 hours. 
 
Fusion  
After 24 hours incubation of the effector cells, these cells were lifted using 0.02% EDTA, 
washed and centrifuged at 1200 rpm for 5 minutes, before they were added to each well of the 
target cells in the p24w, 10
5
 cells per well in a total volume of 500 μl 10% supplemented 
DMEM and 100μg/ml rifampicine, and left to incubate for 6 hours at 37°C. After incubation, 
the medium was removed, and the cells were left at -20°C overnight.  
 
Measurement 
Using the commercial kit Dual Glo® Luciferase Assay System (Promega), 200 μl of 20% 
(v/v) lysis buffer (25 mM Tris-phosphate (pH 7.8), 1% (v/v) Triton X-100, 1 mM EDTA, 1 
mM DTT, 8 mM MgCl2, 15% (v/v) glycerol) diluted in sterile water was added to each well, 
and the cells were left to incubate for 20 minutes in room temperature with gentle agitation. 
The lysates were then collected and 20 μl of each lysate was added to white luminate plates of 
96 wells, quadruplicated. The Firefly Luciferase substrate reagent was then added, 20 μl per 
point, and Firefly Luciferase luminescence was immediately measured without filtrating the 
light. The Renilla Luciferase substrate reagent was then added, 20 μl per point, and Renilla 
Luciferase luminescence was immediately measured, filtrating the light at 486 nm. 
Measurements were done by the fluorimetre Wallac Envision 2104 Multilabel Reader. 
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Normalized Firefly/Renilla Luciferase ratios for each point were calculated, and relative ratios 
were finally calculated (Section 1.3.3).  
 
2.11  Internalization Assay 
 
2x10
5
 cells were resuspended in 6 ml of depletion medium (0.1% (v/v) BSA and 10 mM 
HEPES). 1 ml was added to six 1.5 ml Eppendorf tubes. 100 nM CCL5 was added to each 
Eppendorf tube and incubation was performed at 37°C with constant shaking. Aliquots (the 
content of 1 tube) were withdrawn at 0 min, 1 min, 5 min, 15 min, 30 min and 60 min, and the 
reaction was stopped by adding 1 ml cold PBS (4°C) to each Eppendorf tube. Cells were then 
washed with PBS at 4°C and centrifuged at 1200 rpm for 5 minutes. Samples from each 
incubation time were placed in transparent plates of 96 wells with v-shaped bottoms. Receptor 
levels of CCR5, CD4 and CXCR4 were determined by Flow Cytometry staining (Section 
2.6), using specific monoclonal antibodies against CCR5, CD4 and CXCR4 in the cytometer 
Coulter Epics XL-MCL  
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RESULTS 
 
 
 
 
 
 
 
 
It is better to understand a little than to misunderstand a lot. 
-Anatole France 
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3.1  Receptor expression patterns and functionality of cells containing 
receptors fused with fluorescent proteins. 
 
Prior to evaluation of receptor homo- and heterodimerization, the functionality of cells 
transfected with a fluorescent fusion receptor was assessed. HEK 293T cells were transiently 
transfected with CCR5 CFP and CXCR4 CFP (Section 2.4) and their expression detected by 
flow Cytometry staining (Section 2.6) (Fig. 3.1) and confirmed by confocal microscopy (Fig. 
3.2) 
A)        B) 
 
 
 
 
 
 
 
 
Figure 3.1: Representative staining results of A) CCR5 CFP, marked with monoclonal antibody IgG1 
conjugated with SPRD. B) CXCR4 YFP, marked with monoclonal antibody IgG2A conjugated with 
FITC. Gray peaks represent the isotypes and the striped peaks represent the fluorochrome conjugated 
receptors. 
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A)          B) 
 
 
 
 
 
 
Figure 3.2: Representative images of A) CCR5-CFP and B) CXCR4-YFP by confocal microscopy. The 
images show that both CCR5 and CXCR4 are expressed at the cell surface, as well as intracellularily.  
 
Functionality was then evaluated by a calcium flux assay (Section 2.5).  HEK 293T cells 
transiently transfected with CCR5-CFP and HEK 293T cells transiently transfected with 
CXCR4-CFP responded normally to stimuli of CCL5 (50 nM) and CXCL12 (50 nM), 
respectively (Fig. 3.3), producing an equal response as the corresponding wildtype receptors 
upon ligand stimulation.  All together, these data indicated that both receptors coupled to 
fluorescent molecules were fully functional and expressed correctly at the cell surface. Hence, 
they appear undistinguishable from wildtype receptors in terms of expression pattern and 
important activities. 
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A)       B) 
 
 
 
 
 
 
 
 
Figure 3.3: Calcium flux of A) CXCR4 with 50 nM CXCL12 and B) CCR5 with 50 nM CCL5. Both 
receptors respond normally to stimulation by their respective ligands. 
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3.2  Receptor Homo- and Heterodimerization 
 
FRET techniques were used to analyze dimerization of CCR5 and CXCR4. To detect homo- 
and heterodimers in live cells, FRET saturation curves using HEK 293T cells transiently 
transfected with constant amounts of the donor protein (CFP-coupled CCR5 or CXCR4) and 
increasing amounts of the acceptor protein (YFP-coupled CCR5 or CXCR4) were generated 
(Section 2.7) Positive FRET was observed for both homodimers of CXCR4 and CCR5, and 
also for the heterodimer CCR5/CXCR4 (Fig. 3.4). Both homodimers showed differences in 
FRETmax values (X4/X4, 0.7418 ± 0.0159; R5/R5, 0.51 ± 0.0517), but similar FRET50 values 
(X4/X4, 0.5245 ± 0.0348; R5/R5 0.6693 ± 0.1574). The FRET results for the CCR5/CXCR4 
heterodimer (FRETmax 0.8229 ± 0.0958, FRET50 2.904 ± 0.671) indicated higher affinity of 
both receptors to form homodimers, rather than heterodimers. In the negative controls 
(CXCR4 CFP / the metatropic glutamate receptor conjugated to YFP and CCR5 CFP / the 
metatropic glutamate receptor conjugated to YFP) no FRET was observed (Fig. 3.5). This 
indicates specificity of the molecular interaction between the chemokine receptors. These data 
also demonstrate that FRETmax was detected in cells at ≈ 1:1 YFP/CFP ratio.  
To confirm the results of heterodimerization from the saturation curves, HEK 293T cells were 
transiently transfected with amounts of CCR5 CFP and CXCR4 YFP corresponding to an 
YFP/CFP ratio of 1:1. FRET was then determined by the acceptor photobleaching method 
(Section 2.8) and confocal microscopy. The results showed a FRET intensity of 15.2% ± 3.9 
(Fig. 3.6) 
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A)    
 
 
 
 
 
 
B)  
 
 
 
C) 
 
 
 
 
 
 
D) 
 
    
 
 Values (95 % Confidence Intervals) 
FRETmax 0.7418 ± 0.0159 
FRET50 0.5245 ± 0.0348 
 Values (95 % confidence intervals) 
FRETmax 0.51 ± 0.0517 
FRET50 0.6693 ± 0.1574 
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 E) 
 
 
 
 
 
 F) 
 
 
 
Figure 3.4: Saturation Curve of A) Homodimer CXCR4; C) Homodimer CCR5; E) Heterodimer CCR5 
CFP/CXCR4 YFP; Values of FRETmax and FRET50 with 95% confidence intervals of B) Homodimer 
CXCR4; D) Homodimer CCR5; F) Heterodimer CCR5 CFP/CXCR4 YFP.  
 
 
 
 
 
 
 
 
 
 
 Values (95 % confidence intervals) 
FRETmax 0.8229 ± 0.0958 
FRET50 2.904 ± 0.671 
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A) 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
Figure 3.5: Saturation Curve of A) The heterodimer of CXCR4 CFP / the metatropic glutamate 
receptor conjugated to YFP; B) The heterodimer of CCR5 CFP / the metatropic glutamate receptor 
conjugated to YFP. Neither CXCR4 nor CCR5 form heterodimers with the metatropic glutamate 
receptor and these saturation curves hence serve as negative controls. 
 
 
 
 
 
 
 
68 
 
 
 
 
 
 
Figure 3.6: Representative images of FRET between CCR5CFP and CXCR4YFP, using confocal 
microscopy and the photobleaching method. The square in the middle shows the area of bleaching of 
YFP.  
 
4.3 Receptor expression modulates receptor homo-and heterodimers 
 
HEK 293T cells were transiently transfected with constant concentrations of CXCR4 CFP and 
increasing CXCR4 YFP concentrations in the presence of 9 μg CCR5 DNA. The receptor 
levels of CCR5 were established by flow Cytometry staining (Section 2.6) (Fig. 3.7) FRET 
saturation curves of the homodimer CXCR4CFP/CXCR4YFP in the presence of CCR5 were 
then evaluated. These resulted in a FRETmax value of 0.8496 ± 0.0244 and a FRET50 value 
1.131 ± 0.098 (Fig. 3.8). CCR5 co-expression hence induced a statistical difference in the 
FRET50 value, suggesting that CCR5 alters CXCR4 homodimerization. All together, these 
results indicate that receptor expression modulates CCR5 and CXCR4 conformations at the 
cell surface. 
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Figure 3.7: Representative staining of receptor levels of CCR5 in the cells of the saturation curve of 
CXCR4 + CCR5. The gray peak represents the isotype, and the striped peak represents the level of 
CCR5. 
 
A)  
 
 
 
 
 
B) 
    
 
Figure 3.8: A) Saturation Curve of homo CXCR4 + CCR5. B) Values and 95 % confidence intervals of 
FRETmax and FRET50. 
 
 Values (95 % confidence intervals) 
FRETmax 0.8496 ± 0.0244 
FRET50 1.131 ± 0.098 
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Figure 3.9: Saturation Curves of homo CXCR4 and homo CXCR4 + CCR5 put together in one graph. 
 
4.4 CCR5 co-expression reduces T- tropic HIV- 1 viral infection 
 
A possible modulation of the ability of T-tropic HIV-1 to infect the cells by dynamic 
regulation of CXCR4 homodimers by CCR5 co-expression was then assessed. To evaluate the 
CCR5 effect on T-Tropic HIV-1 viral entry, a pilot experiment was designed, using stable 
HEK 293 cells expressing CD4 and CXCR4, comparing these with other stable HEK 293 cell 
lines, co-expressing CD4, CXCR4 and CCR5. The levels of all three receptors were 
determined in all four cell lines by flow Cytometry staining (Section 2.6) using specific 
monoclonal antibodies against CCR5, CXCR4 and CD4 (Fig. 3.10). Cell-cell fusion assays 
(2.10) were performed using these cell lines as target cells and HEK 293T cells infected with 
recombinant vaccinia virus expressing the T-tropic envelope protein gp120 (IIIB) as effector 
cells. The infection levels detected in the cell lines expressing CD4 and CXCR4 was 
drastically reduced in cells expressing CCR5 (Fig. 3.11), indicating that CCR5 reduces T-
tropic HIV-1 infection. However, as the level of CD4 receptors at the cell surface of both cell 
lines containing CCR5 differed from the cells expressing only CD4 and CXCR4, another 
strategy was established, in order to assure the role of CCR5 in the decrease of infection. 
HEK 293 cells stably expressing CD4 and CXCR4 were transiently transfected with 
increasing amounts of CCR5 (0.5 μg – 2.0 μg). The expression levels of all three receptors 
were determined by flow Cytometry staining (Section 2.6) using specific monoclonal 
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antibodies against CCR5, CXCR4 and CD4 (Fig. 3.12), and cell-cell fusion experiments were 
performed. These experiments clearly showed a correlation between reduction of infection 
and the levels of CCR5 expressed at the cell membrane (Figs. 3.13 and 3.14). The results thus 
indicated that CCR5 co-expression modulates CXCR4 homodimers at the cell surface, and 
reduces the ability of virus expressing T-tropic gp120 envelope proteins to infect the cell.  
To confirm these data, the same cell-cell fusion experiments were performed in cells treated 
and untreated with CCL5, the specific ligand of CCR5, hence provoking internalization of this 
receptor (Section 2.11). A pilot experiment in order to determine the amount of CCL5 needed 
to detect internalization by flow Cytometry was performed, and it was found that incubating 
the cells with 100 nM CCL5 for 60 minutes at 37°C caused an internalization of 48.3%. 
Receptor levels of CD4 and CXCR4 were maintained at the cell surface (Fig. 3.15). HEK 293 
cells stably expressing CD4 and CXCR4 were then transiently transfected with increasing 
amounts of CCR5 (0.5 μg – 2.0 μg) and treated with 100 nM CCL5 for 60 minutes at 37 °C. 
The expression levels of all three receptors were determined by flow Cytometry staining using 
specific monoclonal antibodies against CCR5, CXCR4 and CD4 (Section 2.6), and cell-cell 
fusion experiments were performed (Section 2.10). Flow Cytometry staining results showed 
an internalization of CCR5 of about 50% (Fig. 3.16). Receptor levels of CD4 and CXCR4 
were maintained at the cell surface (not showed). Cell-cell fusion results showed that 
infection levels in cells treated with CCL5 were restored to the infection level of cells without 
CCR5 (Figs. 3.17 and 3.18).  
All together, these results indicate that membrane expression of CCR5 modulate the 
conformations of CXCR4 and hence reduces the ability of T-tropic HIV-1 to infect the cell.  
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A)     B)     C) 
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G)     H)       I) 
 
 
 
 
 
 
 
J)     K)      L) 
 
 
 
 
 
 
Figure 3.10: Receptor levels of A), D), G), J) CD4; B), E), H), K) CCR5; and C), F), I), L) CXCR4 of 
the four cell lines A), B), C) 293T Italy; D), F), G) 293 CD4; G), H), I) 293 CD4 ( 1.5 μg CCR5); and 
J), K), L) 293 CD4 (5.0 μg CCR5).  Gray peaks represent the isotypes and the striped peaks represent 
the fluorochrome conjugated receptors. All cell lines express CXCR4 endogenously. 293 T Italy cells 
lack both CD4 and CCR5, and can therefore serve as a negative control for cell-cell fusion 
experiments. 293 CD4 cells express high amounts of CD4 stably, but lack CCR5.This cell line is 
therefore a positive control for cell-cell fusion experiments. 293 CD4 (1.5 μg CCR5) cells express 
CD4 and modest amounts of CCR5 stably, while 293 CD4 (5.0 μg CCR5) cells express CD4 and 
higher amounts of CCR5 stably. 
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Figure 3.11: A representative cell-cell fusion experiment showing the relative ratios of different cell 
lines upon fusion with effector cells. A clear decrease of infection can be seen, as the relative ratio 
changes from ca. 20 in the cells only expressing CD4 and CXCR4, to ca. 4 in the cells expressing 
CCR5 in addition to CD4 and CXCR4. 
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A)      B)       C) 
 
 
 
 
 
 
 
D)      E) 
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F)     G)      H) 
 
 
 
 
 
 
 
I)      J) 
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K)     L)      M) 
 
 
 
 
 
 
   
  N)        O) 
 
 
 
 
  
 
 
Figure 3.12: Receptor levels of A), B), C), D), E) CD4; F), G), H), I), J) CCR5; and K), L), M, N), O) 
CXCR4; at A), F), K) 2.0 μg empty vector pcDNA3; B), G), L), 0.5 μg CCR5; C), H), M) 1.0 μg CCR5; 
D), I), N) 1.5 μg CCR5, E)  J), O) 2.0 μg CCR5. Gray peaks represent the isotypes and the striped 
peaks represent the fluorochrome conjugated receptors. 
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Figure 3.13: A representative cell-cell fusion experiment showing the relative ratios of 293 CD4 cells 
transiently transfected with increasing concentrations of CCR5, upon fusion with effector cells. As 
transfection of CCR5 increases (Fig. 3.14), infection levels decrease.  
 
 
 
 
 
Figure 3.14: Receptor levels of the 293 CD4 cells in the cell-cell fusion assay (Fig. 3.13) 
 
 
 
 
 
 
Percentage of transfection CCR5 (%) 
CD4 + CCR5 0.5 μg 40.92 
CD4 + CCR5 1.0 μg 23.37 
CD4 + CCR5 1.5 μg 14.04 
CD4 + CCR5 2.0 μg 15.06 
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Figure 3.15: Representative experiment of internalization of CCR5 by stimulation with 100 nM CCL5. 
Receptor levels of CCR5, CD4 and CXCR4 at 0 min, 1 min, 5 min, 15 min, 30min and 60 min of 
incubation with CCL5at the cell surface. CCR5 internalizes, while CD4 and CXCR4 receptor levels 
are maintained at the cell surface. 
Figure 3.16: Representative experiment of internalization of CCR5 upon stimulating HEK 293 CD4 
cells transiently transfected with increasing concentrations of CCR5 (0.5 – 2.0 μg) with CCL5 for 60 
minutes. CCR5 internalizes to about 50% in cells transfected with 0.5 μg CCR5. 
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Figure 3.17: A representative cell-cell fusion experiment showing percentage of infection in cells 
treated with 100 nM CCL5 (Fig. 3.16) and cells untreated with CCL5 (Fig. 3.18).  Infection levels in 
cells treated with CCL5 is clearly restored to infection levels of cells without CCR5. 
 
 
Cell Samples Percentage of transfection CCR5 (%) 
0.5 μg CCR5 27.66 
1.0 μg CCR5 24.87 
1.5 μg CCR5 22.02 
2.0 μg CCR5 21.25 
 
Figure 4.18: Transfection levels of CCR5 in cells used in the cell-cell fusion assay (Fig. 3.17).  
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DISCUSSION 
 
Although monomeric GPCRs can activate heterotrimeric G-proteins [64], many reports show 
evidence of their assembly into dimeric complexes, and even oligomerization was recently 
demonstrated [65]. Chemokine receptors are not an exception, and several reports 
demonstrate the existence of homo- and heterodimers in the absence of ligands [34]. This is 
the case of CCR5 and CXCR4, the two co-receptors for HIV-1 infection.  
In this project, the expression patterns of CCR5 and CXCR4 has been evaluated, in addition 
to the conformations that they can adopt at the cell surface, their dynamics and the effect of 
this on T-tropic HIV-1 infection. Cell functionality and receptor levels were evaluated by 
flow Cytometry.  
The first experiments revealing that dimerization of GPCRs existed were based on 
immunoprecipitation and Western Blotting. The SDS-PAGE technique is based on the distinct 
migration behaviour of the proteins when an electric field is applied. This technique was 
combined with Western Blots, in which the use of specific monoclonal antibodies allows 
detection of specific proteins. The results showed proteins with a higher molecular mass than 
would be expected of the monomeric receptor, and the molecular mass corresponded to that of 
multiple equal receptors [65]. In the cases of receptors lacking a specific antibody, these were 
marked with epitopes at the extreme N-terminus, and identified by antibodies specific to this 
epitope. The use of bifunctional compounds, also called “crosslinkers”, (ex. DSS) also 
became a good option, as fixing the receptor complexes made the interactions more stable, 
and easily detectable [66]. These techniques are still in use, although they present some 
difficulties. They are not applicable for cells in vivo, the use of detergents to solubilise the 
membrane receptors could disturb detection, and the need for specific antibodies in order to 
immunoprecipitate the receptors can provide a problem. Nowadays, techniques based on 
biophysical aspects, like ex. Resonance Energy Transfer (RET), are considered more 
appropriate for this kind of experiments.  
In this project, FRET techniques were used for the evaluation of protein/protein interactions 
on the cell surface. These techniques show energy transfer between two fluorescent proteins, 
if they are located sufficiently close and correctly oriented to each other, as is the case in an 
oligomeric complex. First, receptor expression patterns and receptor functionality upon 
82 
 
stimulation with the ligands of both CCR5 and CXCR4 were evaluated on cells transfected 
with CCR5 and CXCR4 coupled to CFP and YFP. Neither receptor expression patterns nor 
receptor functionality varied from the wildtype receptors. The FRET method of saturation 
curves was used to determine homo- and heterodimerization between CCR5 and CXCR4. In 
these curves, based on constant donor concentration and increasing acceptor concentrations, it 
was found that CXCR4 and CCR5 form homodimers and heterodimers. By analogy to BRET 
parameters, one can assume that if energy transfer reaches saturation and the curve is 
hyperbolic, FRET50 values would allow estimation of the apparent affinities between the 
receptors involved. Based on this, it was concluded that both CCR5 and CXCR4 form homo- 
and heterodimeric complexes at the cell surface, and that the differences in FRET50 values 
observed between the saturation curves of the homo- and heterodimers indicated that both 
receptors have higher affinity towards forming homodimers than forming heterodimers. Thus, 
these data concur with previous reports showing that these complexes exist in the absence of 
ligands and that the affinity to form homodimers is higher than that of forming heterodimers 
[34, 35]. 
Acceptor photobleaching FRET data also confirmed CXCR4/CCR5 heterodimerization at the 
cell membrane. Results from this technique also showed that CXCR4 located itself better than 
CCR5 in the cell membrane. Although FRETmax values between two different homodimers 
cannot be compared due to their mathematical formulas, it is possible that the data obtained 
from the saturation curves are affected by the expression pattern of the receptors in question. 
Bearing in mind this, it is interesting that the FRETmax value of CCR5 was indeed much lower 
than that of CXCR4.  
The FRET results of the saturation curves of the homodimer CXCR4 in competition with 
CCR5 showed that co-expression of CCR5 decreased the apparent affinity of CXCR4 to form 
homodimers, as the FRET50 value of the homodimer CXCR4 in presence of CCR5 increased 
significantly compared to the homodimer CXCR4 alone. This could mean that some CXCR4 
receptors form heterodimers with CCR5, affecting the homodimeric conformations of 
CXCR4. These data hence indicated that chemokine receptor co-expression is sufficient to 
allow heterodimeric complex formation and that homo- and heterodimers coexist at the cell 
membrane in the absence of ligands. All together, the results showed that homo- and 
heterodimerization is a dynamic system, depending among other things on the receptors 
expression at the cell surface.  
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The central question at this point was whether the apparent effect of CCR5 on the CXCR4 
homodimer could affect T-tropic HIV-1 infection. CCR5 and CXCR4 are the two main co-
receptors for HIV-1 infection, and previous published evidence suggests that receptor 
dimerization can influence this. [67]. Evaluation of HIV-1 entry was done by the method of 
cell-cell fusion between effectors containing the vaccinia virus expressing the T-tropic gp120 
and target cells expressing CD4 and CXCR4 in the absence and presence of CCR5. Firefly 
and Renilla Luciferases served as reporters of infection. Hence, advantage was taken of an in 
vitro assay, thus avoiding the use of the natural virus. The results showed a clear correlation 
between CCR5 expression and a decrease in T-tropic HIV-1 infection. Maintaining CD4 and 
CXCR4 levels unchanged at the cell surface while increasing the concentration of CCR5 
discarded an unspecific effect and assured the role of CCR5 in the decrease of infection. To 
confirm these observations, cells co-expressing CD4, CXCR4 and CCR5 were treated with 
CCL5, the specific ligand of CCR5, and all three receptor levels were evaluated by Flow 
Cytometry. As expected, CCL5 induced the internalization of CCR5 without affecting the 
levels of CD4 and CXCR4 at the cell surface. Parallel cell-cell fusion of the CCL5 treated 
cells with effectors showed that infection levels were restored to the control levels in cells not 
expressing CCR5. CCL5 mediated downregulation of CCR5 was thus sufficient to restore the 
CXCR4 conformation allowing T-tropic HIV-1 entry and infection.  
All together, these results suggest that the conformation dynamics of the main co-receptor of 
T-tropic HIV-1 in the presence of CCR5, can decrease the capacity of HIV-1 to enter the cell, 
and hence infection.  
Future Perspectives 
Currently, this research project opens new questions. As previous mentioned, HIV-1 infection 
requires the presence of CD4 and one of the co-receptors (CXCR4 or CCR5). Until now, only 
the ability of CCR5 to decrease the apparent affinity of CXCR4 homodimer conformation by 
heterodimerization, and hence alter further interaction between CXCR4 and CD4 has been 
studied. However, an alternative hypothesis could be that CCR5 also modulates CD4 
conformations. Some reports suggest that CD4 interacts with both CCR5 and CXCR4 [68], 
and it is thus necessary to analyze this possibility, by for example generating saturation curves 
of the homodimer CD4/CD4 and the heterodimers CD4/CCR5 and CD4/CXCR4, comparing 
the apparent affinities between the different dimers. Another possibility is the formation of a 
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heterotrimeric complex between all three receptors (CD4, CCR5 and CXCR4) at the cell 
surface. If CXCR4 and CD4 are capable of forming heterodimers and gp120 binds to these 
receptors in this conformation, the sudden presence of CCR5 could possibly alter the 
conformation of these receptors, by forming heterodimers with either one of the receptors, or 
by joining the complex, forming a heterotrimer. In this last case, CCR5 may be capable of 
altering the position of CD4 and CXCR4 enough to block the correct binding of gp120. The 
possibility of a heterotrimeric complex can be assessed by the use of multicolour Bimolecular 
Fluorescence Complementation (BiFC). In this technique, CXCR4 for example, would be 
coupled to a so-called split YFP, consisting of a fragment of YFP (the N-terminal part of 
YFP), whereas CCR5 would be coupled to the complementary fragment (the C-terminal part 
of YFP), thus only allowing for YFP detection upon interaction between CXCR4 and CCR5. 
CD4 would then be coupled to CFP, and thus, positive FRET would be observed between all 
three receptors if these were to form an oligomeric complex.  
During my project, it has become clear that CCR5 is capable of decreasing T-tropic HIV-1 
infection through interaction with CXCR4, CD4 or both. The exact mechanism for this effect 
is yet to be determined by the techniques described above.   
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CONCLUDING REMARKS 
 
 CXCR4 and CCR5 have been generated as CFP and YFP fusion proteins, and these 
proteins have been used to determine homo- and heterodimerization of CXCR4 and 
CCR5 at the cell surface. 
 The expression patterns of CCR5-CFP and CXCR4-YFP do not differ from those of 
the wild type receptors. 
 CCR5-CFP and CXCR4-CFP responded normally to the corresponding ligands (CCL5 
and CXCL12, respectively) in terms of Ca
2+
 flux, indicating that they are fully 
functional.  
 CCR5 and CXCR4 form homo-and heterodimers at the cell surface. 
 Both homo- and heterodimers co-exist at the cell membrane in the absence of ligands. 
 CCR5 co-expression reduces the apparent affinity of CXCR4 towards forming 
homodimers, indicating possible conformation changes of CXCR4 in the presence of 
CCR5. 
 CCR5 and CXCR4 homo-and heterodimerization are dynamically regulated by 
receptor expression. 
 T-tropic HIV-1 entry is reduced in cells co-expressing CCR5, in addition to CD4 and 
CXCR4, suggesting that CCR5/CXCR4 heterodimerization modulate T-tropic HIV-1 
infection.  
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